Stock Movements, Promising Partnerships, Upcoming Conferences, and Successful Acquisitions - Analyst Notes on Garmin, Waters, Flextronics, Cepheid and Allegion

NEW YORK, May 14, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Garmin Ltd. (NASDAQ: GRMN), Waters Corp. (NYSE: WAT), Flextronics International Ltd. (NASDAQ: FLEX), Cepheid (NASDAQ: CPHD) and Allegion plc (NYSE: ALLE). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2528-100free.

--
Garmin Ltd. Analyst Notes
On May 9, 2014, Garmin Ltd.'s (Garmin) stock declined 0.09%, ending the day at $55.83. Over the previous five trading sessions, shares in Garmin declined 2.95% compared to the Nasdaq Composite which also declined 1.26% during the same period. The full analyst notes on Garmin are available to download free of charge at:

http://www.analystsreview.com/2528-GRMN-14May2014.pdf

--
Waters Corp. Analyst Notes
On May 9, 2014, Waters Corp.'s (Waters) shares increased 1.50%, ending the day at $103.46. For the past month, shares in Waters have declined 9.48% compared to the Dow Jones Industrial Average which has increased 0.89% during the same period. The full analyst notes on Waters are available to download free of charge at:

http://www.analystsreview.com/2528-WAT-14May2014.pdf

--
Flextronics International Ltd. Analyst Notes
On May 7, 2014, Flextronics International Ltd. (Flextronics) announced that its Medical Group will supply design and manufacturing services to Ichor Medical Systems to help develop its next generation TriGrid™ DNA Delivery System- an electroporation device that is utilized to provide DNA vaccines and treatments for various disease indications. The TriGrid technology was recently licensed by Pfizer for the intracellular delivery of their DNA-based cancer vaccines. Mark Kemp, President of Flextronics Medical, commented, "Flextronics is proud to collaborate and provide supply chain solutions that include design and manufacturing for this exciting new technology." Kemp added, "With the introduction of TriGrid electroporation, a wide range of promising DNA-based therapies can now be made much more effective. We applaud Ichor on their innovative work to advance therapies that lessen human disease and suffering. We look forward to helping them develop their product, from design to delivery." The full analyst notes on Flextronics are available to download free of charge at:

http://www.analystsreview.com/2528-FLEX-14May2014.pdf

--
Cepheid Analyst Notes
On April 29, 2014, Cepheid (Cepheid) announced that its executives will speak at the Bank of America Merrill Lynch Health Care Conference in Las Vegas on May 14, 2014 at 9.20 a.m. PT and UBS Healthcare Conference in New York on May 21, 2014 at 10:00 a.m. ET. Interested parties can access the live webcasts of the events via the Company website, where replays of the webcasts will also be available after the presentation for at least 90 days. The full analyst notes on Cepheid are available to download free of charge at:

http://www.analystsreview.com/2528-CPHD-14May2014.pdf

--
Allegion plc Analyst Notes
On April 30, 2014, Allegion plc (Allegion) announced that it acquired Fire & Security Hardware Pty Limited (FSH) - an electromechanical locking provider in Australia. The Company stated that as a result of this acquisition, Allegion now has ownership of the FSH brand and product portfolio, along with several ingenious patent-protected electric strikes and latches. Dave Petratis, Chairman, President and CEO of Allegion commented, "Allegion's acquisition of FSH strengthens our position in Australia and adds new electronic technologies that will integrate well with our global product lines. It's a great example of the innovative and opportunistic acquisitions we said we'd complete at our investor day in March." Petratis continued, "This transaction also shows our disciplined approach to M&A, focused on product expansion and increasing our presence in both emerging markets and technologies." The full analyst notes on Allegion are available to download free of charge at:

http://www.analystsreview.com/2528-ALLE-14May2014.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review